5/9/2022 4:14:12 PM
Geron Q1 Loss/share $0.09, Same As Last Year
3/10/2022 4:11:04 PM
Geron Corp. Q4 Loss/share $0.10 Vs. Loss $0.07 Year Ago
12/2/2021 7:33:26 AM
Geron Appoints Edward Koval As EVP And Chief Business
Officer
10/18/2021 7:36:20 AM
Geron Completes Patient Enrollment In IMerge Phase 3 Trial In Lower Risk Myelodysplastic Syndromes
5/12/2021 11:05:31 AM
Geron Announces Two Presentations At Upcoming European Hematology Association Annual Congress
5/10/2021 4:10:26 PM
Geron Q1 Loss/Shr $0.09 Vs Loss $0.08 Last Year
4/13/2021 7:34:51 AM
Geron Says First Patient Has Been Dosed In IMpactMF Phase 3 Clinical Trial In Refractory Myelofibrosis